TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01429610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab+mVPDL
Description: 1. Induction:~   * Dauno 90 mg/m2/d by civ (d1-3)~  * Vinc 2 mg iv (d1, 8)~  * Pred 60 mg/m2/d po (d1-14)~  * for Ph(-): L-asp 4,000 units/m2/day im/sc (d17-28) for Ph(+): Imatinib 600mg/d po qd (d8-continue till the end of maintenance or just before alloHCT)~  * Rituximab 375mg/m2/d (d8)~2. Consolidation A (cycle1)~   * D 45 mg/m2/day by continuous iv (d1, 2)~  * V 2 mg iv (d1, 8)~  * P 60 mg/m2/day po (d1-14)~  * for Ph(-): L-asp (d1-14) for Ph(+): Imatinib~  * Rituximab 375mg/m2/d (d8)~3. Consolidation B (cycles2\&4)~   * Cyt 2,000 mg/m2/d iv over 2 hr (d1-4)~  * Eto 150 mg/m2/d iv over 3 hr (d1-4)~  * Rituximab 375mg/m2/d d8~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)~  * Leucovorin 50 mg/m2 iv every 6hr for 3 doses,~  * Rituximab 375mg/m2/d (d8\&22)~5. Maintenance (for 2 years)~   - for Ph(-): 6- Mercaptopurine 60 mg/m2 po qd Methotrexate 20 mg/m2 po qw for Ph(+): imatinib 600mg/d po qd~6. Consider alloHCT
Study: NCT01896856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110 Dose Escalation
Description: * Dose level 1 (DL1): 45 mg/m\^2 administered as a subcutaneous injection~* Dose level 1G (DL1G): 45 mg/m\^2 administered as a subcutaneous injection + growth factor support~* Dose level -1 (DL-1): 30 mg/m\^2 administered as a subcutaneous injection~* Dose level -1G (DL-1G): 30 mg/m\^2 administered as a subcutaneous injection + growth factor support

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: 160 mg taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: 35 mg/m\^2 taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Description: 45 mg/m\^2 administered as a subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGI-110
Description: 45 mg/m\^2 administered as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 125 mg/m\^2 administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 125 mg/m\^2 administered IV
Study: NCT02402712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab [Perjeta]
Description: Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: Subcutaneous administration of 600 mg/5 mL every 3 weeks
Study: NCT02330107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAT & LAT
Description: For MAT, the magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAT & LAT
Description: For MAT, the magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MAT & LAT
Description: For MAT, the magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear.
Study: NCT02606214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-354
Study: NCT03852121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Description: Bibliotherapy is the use of reading materials for therapeutic benefits. In this study, an evidence-based modified manual will be used as the reading material. The manual adopts the self-directed problem-solving approach to dementia caregiving, examples of how other caregivers solve the specific problem for each chapter is included in the corresponding chapter. Bibliotherapy also involves guided learning by reading written information, enabling caregivers to solve their caregiving problems step-by-step, so telephone coach is designed to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves.
Study: NCT02715999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory.All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally at the posterior border of the quadratus lumborum muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block
Description: After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally between internal oblique and transversus abdominis muscles.
Study: NCT03460925

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT plus chemotherapy
Description: Neoadjuvant stereotactic body radiotherapy (SBRT, 30 Gy in 5 fractions) plus chemotherapy with Folfirinox
Study: NCT04798313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW031
Description: Subjects would receive a single 60mg (1 mL) of MW031 through subcutaneous injection, on the first day of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.
Study: NCT03550742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fuco-N-Tetraose
Description: Daily bolus of Fuco-N-Tetraose
Study: NCT04178135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rLH
Description: rLH supplement from day 1 of stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rLH
Description: rLH supplement from day 6 of stimulation
Study: NCT04485234

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Coronary Flow Reserve, Microvascular resistance
Description: Calculation of the resting mean distal coronary to aortic pressure ratio (resting Pd/Pa), fractional flow reserve (Pd/Pa at hyperemia), Coronary flow reserve (peak flow/resting flow), microvascular resistance (Pd/flow).
Study: NCT02375204

Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: ifosfamide
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: ifosfamide
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: pegylated G-CSF
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: pegylated G-CSF
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: carboplatin
Description: IV

Intervention type: DRUG
Group type: OTHER
Intervention: etoposide phosphate
Description: IV

Intervention type: PROCEDURE
Group type: OTHER
Intervention: stem cell reinfusion
Description: surgical procedure
Study: NCT01195831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xamiol® gel
Description: Once daily application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol scalp solution
Description: Twice daily application
Study: NCT01208701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Zarator, 80 mg pr day for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unikalk
Description: 1 tablet Unikalk pr day for 5 days
Study: NCT00425711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
Study: NCT03587571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical intervention
Description: Open reduction and plate osteosynthesis.
Study: NCT04638868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microsieve device
Description: Both portal venous and peripheral blood will be processed through a label-free size-based silicon microsieve microfiltration device, which will isolate both epithelial-type and mesenchymal-type pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cell surface marker-based platform
Description: Both portal venous and peripheral blood will be processed through a cell surface marker-based platform, which contains antibodies for epithelial cell markers on pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
Study: NCT04571918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodegradable spacer
Description: Implantation of a biodegradable balloon used as a subacromial spacer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement and biceps tenotomy
Description: Surgery with arthroscopic debridement and biceps tenotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement and biceps tenotomy
Description: Surgery with arthroscopic debridement and biceps tenotomy
Study: NCT01692223

Intervention type: BEHAVIORAL
Intervention: qualitative interviews
Description: A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety \& Depression Scale (HADS), revised Impact of Events Scale (IES-R), \& a questionnaire about their health behaviors, to establish baseline distress levels \& health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider \& discuss resultant therapeutic \& management recommendations for the participants \& their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
Study: NCT01692223

Intervention type: BEHAVIORAL
Intervention: qualitative interviews
Description: A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety \& Depression Scale (HADS), revised Impact of Events Scale (IES-R), \& a questionnaire about their health behaviors, to establish baseline distress levels \& health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider \& discuss resultant therapeutic \& management recommendations for the participants \& their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.

Intervention type: BEHAVIORAL
Intervention: qualitative interviews
Description: A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety \& Depression Scale (HADS), revised Impact of Events Scale (IES-R), \& a questionnaire about their health behaviors, to establish baseline distress levels \& health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider \& discuss resultant therapeutic \& management recommendations for the participants \& their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
Study: NCT02211183

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Best Repair of torn Rotator Cuff

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InSpace™ system
Study: NCT02670915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: For subcutaneous (s.c., under the skin) injection once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: For subcutaneous (s.c., under the skin) injection once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: For subcutaneous (s.c., under the skin) injection once daily.
Study: NCT02606214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TBA-354 Placebo
Study: NCT02670915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: For subcutaneous (s.c., under the skin) injection once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: For subcutaneous (s.c., under the skin) injection once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: For subcutaneous (s.c., under the skin) injection once daily.
Study: NCT02610205

Intervention type: OTHER
Intervention: caring touch
Description: The caring touch was adjusted to suit each participant and lasted for 20-60 minutes, once a week, for a maximum of eight treatment sessions altogether. The tactile massage, a soft tissue massage, without applying direct pressure or stretching to the muscles. The massage can be described as slow, gentle, structured, circulating movements with the palm of the therapist's hand, during which natural oil, or oil with the fragrance of lavender, was applied. The healing touch was based on an established procedure, during which the therapist applied a light pressure to the feet, ankles, knees, hips, stomach, heart area, arms, throat, forehead and scalp. The participant was fully dressed during the healing touch, as the therapist used her/his hand in different positions on the participant's body.
Study: NCT02021825

Intervention type: DRUG
Group type: OTHER
Intervention: Mitoxantrone
Description: The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
Study: NCT00284739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: 2mg or 4mg given twice daily for three days into loculated abscess

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline injection twice daily for three days
Study: NCT04393077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: EFT application was started by showing the meridian points to the participants through the picture. It was advised that these points should be clicked with the index finger and middle finger without hurting, but with certain strokes, and it was ensured that they understood the regions by showing and applying them. Then, the following basic steps, which should be followed by the EFT session (four in total lasting 20 minutes), were carried out in succession with the researcher.
Study: NCT04315493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib maleate fasted in P1, low-fat diet in P2
Description: pyrotinib maleate administration in fasted condition in period 1, pyrotinib maleate administration after low-fat diet in period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib maleate low-fat diet in P1, fasted in P2
Description: pyrotinib maleate administration after low-fat diet in period 1, pyrotinib maleate administration in fasted condition in period 2
Study: NCT02606214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TBA-354 Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TBA-354 Placebo
Study: NCT01407315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoMenDay
Description: Subjects will receive a standardized lunch (100 g of CHO), administration of insulin will be performed by the subject based on insulin to carbohydrate ratio.~An intravenous catheter will be inserted in one forearm and venous sampling will start 1 hour after lunch ingestion. Arterialized-venous blood sampling will be performed every 15 minutes for a period of two hours. Samples will be analyzed for glucose using the Super GL; concomitantly capillary measurements using the GlucoCard G Meter will be performed.~This procedure can be performed on days 3-4 of monitoring; each subject randomized to Procedure A undergoes this procedure once.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoMenDay
Description: Subjects will receive a standard breakfast (75g CHO), the usual morning insulin dose will be post-poned. An increased dose of rapid-acting insulin analogue aiming to produce minor hypoglycaemia based on insulin to carbohydrate ratio will be injected subcutaneously. Arterialized-venous sampling will be performed every 10 minutes for a period of two hours.~Samples will be analyzed for glucose using the Super GL; concomitantly, capillary measurements using the GlucoCard G Meter will be performed.~This procedure will be performed on days 2 and 4 of monitoring; each subject randomized to Procedure B undergoes this procedure twice.
Study: NCT03913312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unrelated cord blood
Description: Unrelated cord blood comes from Shandong cord blood bank. TNC\>1.5\*107/kg;HLA 4-5/6
Study: NCT00243529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell vaccine
Study: NCT01985373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin infusion
Description: Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
Study: NCT00243529

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous dendritic cell vaccine
Study: NCT04004377

Intervention type: OTHER
Intervention: Scale of quality life
Description: The PANQOL scale (Penn Acoustic Neuroma Quality-of-Life) is a specific questionnaire containing 26 items Interviewing 7 areas: hearing, balance, facial expression, anxiety, vitality, pain, and 'general health. The score is encrypted from 0 to 100, and the highest score is a reflection of the best possible quality of life. This score has been translated from French into English and validated according to the reverse translation rules by usual Oddon et al.~Three questions for this score were added, evaluating quality of life parameters that seem particularly interesting: the first regarding the difficulties in driving, the second questioning the recovery of a normal life, and the third assessing difficulties in working life.

Intervention type: OTHER
Intervention: Scale of quality life
Description: The PANQOL scale (Penn Acoustic Neuroma Quality-of-Life) is a specific questionnaire containing 26 items Interviewing 7 areas: hearing, balance, facial expression, anxiety, vitality, pain, and 'general health. The score is encrypted from 0 to 100, and the highest score is a reflection of the best possible quality of life. This score has been translated from French into English and validated according to the reverse translation rules by usual Oddon et al.~Three questions for this score were added, evaluating quality of life parameters that seem particularly interesting: the first regarding the difficulties in driving, the second questioning the recovery of a normal life, and the third assessing difficulties in working life.
Study: NCT01225757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: Echocardiography will be utilized during the procedure to guide fluid management.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiogram
Description: Echocardiography will be utilized during the procedure to guide fluid management.
Study: NCT03833817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking about Cancer (TAC)
Description: The TAC intervention is a six session intervention designed to teach the techniques of distress tolerance and communication skills in order to assist patients and their caregivers in discussing the patients' prognoses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking about Cancer (TAC)
Description: The TAC intervention is a six session intervention designed to teach the techniques of distress tolerance and communication skills in order to assist patients and their caregivers in discussing the patients' prognoses.